BTIG Boosts PT on bluebird bio (BLUE) to $83; Sees Favorable FDA Pathway Derisking Pivotal Study Timeline

bluebird bio Provides Update on LentiGlobin™ Programs and Research and Development Strategy at Gene Therapy Day

Consistently demonstrated improved vector copy number (VCN) in transfusion-dependent -thalassemia (TDT) and severe sickle cell disease (SCD) patient cells in vitro with manufacturing Process 2

Implementing plan to optimize patient outcomes in severe SCD

Achieved general agreement on regulatory path for TDT across all genotypes, ages

Advanced suspension manufacturing process

NEW YORK--(BUSINESS WIRE)-- bluebird bio, Inc.... More